AU2019271812A1 — Pharmaceutical composition of KOR receptor agonist
Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2021-01-07 · 5y expired
What this patent protects
Disclosed in the present invention is a pharmaceutical composition of a KOR receptor agonist, which comprises 4-amino-N-[N2-[N-[N-[N-((R)-2-phenyl propyl)glycyl]-D-phenylalanyl]-D-leucyl]-D-lysyl]piperidine-4-carboxylic acid or available salts thereof, and an acetate buffer solut…
USPTO Abstract
Disclosed in the present invention is a pharmaceutical composition of a KOR receptor agonist, which comprises 4-amino-N-[N2-[N-[N-[N-((R)-2-phenyl propyl)glycyl]-D-phenylalanyl]-D-leucyl]-D-lysyl]piperidine-4-carboxylic acid or available salts thereof, and an acetate buffer solution.
Drugs covered by this patent
- Luzu (LULICONAZOLE) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.